ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source ...

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

The Phase 3 ResQ201A-NSCLC study (NCT06745908) aims to confirm the efficacy and safety of combination ANKTIVA plus CPI therapy previously demonstrated in the trial QUILT 3.055 and provide evidence ...

Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response.

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application for Anktiva in combination with Bacillus Calmette ...

The owner of the Los Angeles Times discusses his fight to cure cancer and why he wants President Donald Trump to succeed in his second term in office.

ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...

The MHRA will now begin assessing the marketing authorization application (MAA) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with bacillus Calmette-Guérin (BCG) for the ...

Specifically, the company will now be able to provide this alternative to urologists for use in combination with IBRX’s bladder cancer treatment, Anktiva. Typically utilized in conjunction with ...